Logo image of MTEM

MOLECULAR TEMPLATES INC (MTEM) Stock Fundamental Analysis

NASDAQ:MTEM - Nasdaq - US6085502085 - Common Stock - Currency: USD

0.1072  -0.03 (-23.43%)

After market: 0.1113 +0 (+3.82%)

Fundamental Rating

2

Taking everything into account, MTEM scores 2 out of 10 in our fundamental rating. MTEM was compared to 558 industry peers in the Biotechnology industry. While MTEM seems to be doing ok healthwise, there are quite some concerns on its profitability. MTEM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MTEM had negative earnings in the past year.
MTEM had a negative operating cash flow in the past year.
In the past 5 years MTEM always reported negative net income.
MTEM had a negative operating cash flow in each of the past 5 years.
MTEM Yearly Net Income VS EBIT VS OCF VS FCFMTEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

MTEM has a Return On Assets (-58.52%) which is comparable to the rest of the industry.
MTEM has a Return On Equity of -219.70%. This is in the lower half of the industry: MTEM underperforms 69.66% of its industry peers.
Industry RankSector Rank
ROA -58.52%
ROE -219.7%
ROIC N/A
ROA(3y)-53.73%
ROA(5y)-55.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTEM Yearly ROA, ROE, ROICMTEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400 600 -600

1.3 Margins

MTEM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTEM Yearly Profit, Operating, Gross MarginsMTEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

MTEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MTEM has been increased compared to 1 year ago.
The number of shares outstanding for MTEM has been increased compared to 5 years ago.
MTEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MTEM Yearly Shares OutstandingMTEM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
MTEM Yearly Total Debt VS Total AssetsMTEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

MTEM has an Altman-Z score of -25.30. This is a bad value and indicates that MTEM is not financially healthy and even has some risk of bankruptcy.
MTEM has a worse Altman-Z score (-25.30) than 89.77% of its industry peers.
MTEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.3
ROIC/WACCN/A
WACC10.24%
MTEM Yearly LT Debt VS Equity VS FCFMTEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

MTEM has a Current Ratio of 1.56. This is a normal value and indicates that MTEM is financially healthy and should not expect problems in meeting its short term obligations.
MTEM has a worse Current ratio (1.56) than 81.87% of its industry peers.
A Quick Ratio of 1.56 indicates that MTEM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.56, MTEM is doing worse than 80.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.56
MTEM Yearly Current Assets VS Current LiabilitesMTEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 78.35% over the past year.
The Revenue for MTEM has decreased by -49.41% in the past year. This is quite bad
The Revenue has been growing by 33.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)78.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.84%
Revenue 1Y (TTM)-49.41%
Revenue growth 3Y44.86%
Revenue growth 5Y33.95%
Sales Q2Q%-91.67%

3.2 Future

MTEM is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -19.70% yearly.
Based on estimates for the next years, MTEM will show a very negative growth in Revenue. The Revenue will decrease by -10.69% on average per year.
EPS Next Y-92.81%
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%
EPS Next 5Y-19.7%
Revenue Next Year-78.76%
Revenue Next 2Y-85.29%
Revenue Next 3Y-46.28%
Revenue Next 5Y-10.69%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MTEM Yearly Revenue VS EstimatesMTEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M
MTEM Yearly EPS VS EstimatesMTEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MTEM. In the last year negative earnings were reported.
Also next year MTEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTEM Price Earnings VS Forward Price EarningsMTEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTEM Per share dataMTEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

MTEM's earnings are expected to decrease with -21.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MTEM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULAR TEMPLATES INC

NASDAQ:MTEM (12/24/2024, 7:26:55 PM)

After market: 0.1113 +0 (+3.82%)

0.1072

-0.03 (-23.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)N/A N/A
Inst Owners56.12%
Inst Owner Change-99.64%
Ins Owners3.96%
Ins Owner Change0%
Market Cap705.38K
Analysts82.86
Price Target18.36 (17026.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.16%
Min EPS beat(2)16.26%
Max EPS beat(2)110.06%
EPS beat(4)4
Avg EPS beat(4)48.67%
Min EPS beat(4)16.26%
Max EPS beat(4)110.06%
EPS beat(8)7
Avg EPS beat(8)48.91%
EPS beat(12)10
Avg EPS beat(12)36.51%
EPS beat(16)12
Avg EPS beat(16)-1.05%
Revenue beat(2)2
Avg Revenue beat(2)57.36%
Min Revenue beat(2)30.42%
Max Revenue beat(2)84.31%
Revenue beat(4)3
Avg Revenue beat(4)68.38%
Min Revenue beat(4)-11.54%
Max Revenue beat(4)170.33%
Revenue beat(8)6
Avg Revenue beat(8)235.75%
Revenue beat(12)8
Avg Revenue beat(12)154.87%
Revenue beat(16)8
Avg Revenue beat(16)104.62%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.1
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS3.87
BVpS1.08
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.52%
ROE -219.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.73%
ROA(5y)-55.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.56
Quick Ratio 1.56
Altman-Z -25.3
F-Score4
WACC10.24%
ROIC/WACCN/A
Cap/Depr(3y)35.57%
Cap/Depr(5y)222.6%
Cap/Sales(3y)8.96%
Cap/Sales(5y)21.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.84%
EPS Next Y-92.81%
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%
EPS Next 5Y-19.7%
Revenue 1Y (TTM)-49.41%
Revenue growth 3Y44.86%
Revenue growth 5Y33.95%
Sales Q2Q%-91.67%
Revenue Next Year-78.76%
Revenue Next 2Y-85.29%
Revenue Next 3Y-46.28%
Revenue Next 5Y-10.69%
EBIT growth 1Y57.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.4%
OCF growth 3YN/A
OCF growth 5YN/A